April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Reduction of Macular Drusen Following Anti-VEGF Intravitreal Injection in ARMD
Author Affiliations & Notes
  • L. J. Rao
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • V. C. Lima
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
  • R. C. Gentile
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
    Ophthalmology, New York Medical College, Valhalla, New York
  • R. Rosen
    Ophthalmology, New York Eye and Ear Infirmary, New York, New York
    Ophthalmology, New York Medical College, Valhalla, New York
  • Footnotes
    Commercial Relationships  L.J. Rao, None; V.C. Lima, None; R.C. Gentile, None; R. Rosen, None.
  • Footnotes
    Support  Supported by the Department of Ophthalmology Research Fund of the New York Eye and Ear Infirmary and the Norma Lazar Ophthalmology Research Fund
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 1881. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. J. Rao, V. C. Lima, R. C. Gentile, R. Rosen; Reduction of Macular Drusen Following Anti-VEGF Intravitreal Injection in ARMD. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1881.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To report an observation and better characterize the finding of diminished macular drusen after intravitreal anti-VEGF therapy for choroidal neovascularization (CNV) in age related macular degeneration (ARMD).

Methods: : After observing a case of diminished drusen after intravitreal anti-VEGF therapy, a retrospective photographic and chart review was conducted to identify similar cases from fundus photography performed before and after intravitreal anti-VEGF therapy for CNV in ARMD.

Results: : Six eyes of six patients were identified. There were four females and two males, with an average age of 74.5 years (range 64-87). Three patients received intravitreal bevacizumab injections, and three received ranibizumab. The mean number of injections was 5 (range 1-12). Drusen diminished in the area of choroidal neovascularization (CNV) without associated subretinal fibrosis. After treatment, visual acuity improved in two eyes, stayed the same in two eyes, and decreased in two eyes. The mean pre-treatment visual acuity was 20/50 (range 20/20-20/160) compared to 20/60 (range 20/20-20/160) after treatment. Three of the eyes had classic subfoveal CNV, one had occult CNV, and two had occult CNV with associated pigment epithelial detachments.

Conclusions: : Diminished drusen can occur after the development of wet ARMD without subretinal fibrosis when treated with anti-VEGF intravitreal therapy. The loss of drusen occurs in the area of CNV and can be associated with both occult and classic CNV. The exact mechanism is not known but most likely may be related to vascular reabsorbtion and clearing of drusen debris during CNV regression and suppression.

Keywords: age-related macular degeneration • drusen • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×